Vein-to-Vein EU | Kisaco Research

Vein-to-Vein Congress EU

Tackling the manufacturing, scale-up, regulatory and logistical bottlenecks to commercialise cell therapies for the mainstream.

Download agenda
London, UK
28-30 January, 2020

Why Attend

The market value for cell therapies is expected to triple in size by 2025 to $8.21 bn, with investment also having increased by 64% since 2017 to $7.6 bn. Cell therapies have a huge commercial potential however scaled manufacturing, automation, logistics, regulation, and quality control continue to be limiting factors. Before cell therapies can make a mainstream clinical impact, patient access increased and truly reach their commercial potential, these obstructions need to be improved.


The Vein-to-Vein Congress will gather manufacturing, operations, site managers and logistical heads from both Biotechs and pharmaceutical companies to address these bottlenecks and facilitate the commercial manufacture of cell therapies.

As the cell therapy industry shifts from manual to automated manufacturing, the Vein-to-Vein Congress will discuss the measures that leading companies have put in place to streamline their manufacturing process, scale-up over time and ensure a water-tight supply chain with tracking and trackability from cell collection to patient. 

The Speakers

 

Ali Mohamed

VP CMC
Immatics Biotechnologies

Ali Mohamed

VP CMC
Immatics Biotechnologies

Ali Mohamed

VP CMC
Immatics Biotechnologies
 

Markwin Velders

MD & VP Operations
Kite Pharma

Markwin Velders

MD & VP Operations
Kite Pharma

Markwin Velders

MD & VP Operations
Kite Pharma
 

Dr David Sourdive, PhD

Executive Vice President Technical Operations
Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016.

Dr David Sourdive, PhD

Executive Vice President Technical Operations
Cellectis

Dr David Sourdive, PhD

Executive Vice President Technical Operations
Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.

 

Emanuele Ostuni

Head of Cell & Gene Therapy Europe
Novartis

Emanuele Ostuni

Head of Cell & Gene Therapy Europe
Novartis

Emanuele Ostuni

Head of Cell & Gene Therapy Europe
Novartis
 

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda
 

Niloofar Davoodi

Cell & Gene Therapy - Global Regulatory CMC Senior Manager
Novartis

Niloofar Davoodi

Cell & Gene Therapy - Global Regulatory CMC Senior Manager
Novartis

Niloofar Davoodi

Cell & Gene Therapy - Global Regulatory CMC Senior Manager
Novartis
 

Stefan Wildt

Head, Pharmaceutical Sciences and Cell Therapies Translational Engine
Takeda

Stefan Wildt

Head, Pharmaceutical Sciences and Cell Therapies Translational Engine
Takeda

Stefan Wildt

Head, Pharmaceutical Sciences and Cell Therapies Translational Engine
Takeda
 

Liesbeth De Jong

Vice President, Manufacturing and R&D
Rexgenero

Liesbeth De Jong

Vice President, Manufacturing and R&D
Rexgenero

Liesbeth De Jong

Vice President, Manufacturing and R&D
Rexgenero
 

Lior Raviv

VP, Development & Operations
Pluristem

Lior Raviv

VP, Development & Operations
Pluristem

Lior Raviv

VP, Development & Operations
Pluristem
 

Louise Bisset

Biopharmaceutical Qaulity Assessor
MHRA

Louise Bisset

Biopharmaceutical Qaulity Assessor
MHRA

Louise Bisset

Biopharmaceutical Qaulity Assessor
MHRA
 

Paul Kemp

CEO
HairCLone

Paul Kemp

CEO
HairCLone

Paul Kemp

CEO
HairCLone
 

Piers Walser

Lead Development Scientist
NHS

Piers Walser

Lead Development Scientist
NHS

Piers Walser

Lead Development Scientist
NHS
 

Qasim Rafiq

Bioprocessing
UCL

Qasim Rafiq

Bioprocessing
UCL

Qasim Rafiq

Bioprocessing
UCL
 

Volker Huppert

COO
Glycostem

Volker Huppert

COO
Glycostem

Volker Huppert

COO
Glycostem
 

Jasmin Kee

VP Manufacturing Operations
Cell Medica

Jasmin Kee

VP Manufacturing Operations
Cell Medica

Jasmin Kee

VP Manufacturing Operations
Cell Medica
 

Jean-Pierre Latere Dwan’Isa

COO
Celyad

Jean-Pierre Latere Dwan’Isa

COO
Celyad

Jean-Pierre Latere Dwan’Isa

COO
Celyad
 

Pierre Heimendinger

VP Process Development
Sangamo Therapeutics

Pierre Heimendinger

VP Process Development
Sangamo Therapeutics

Pierre Heimendinger

VP Process Development
Sangamo Therapeutics
 

Sadia L'Bouch

Senior Director, Manufacturing and Supply
Sangamo Therapeutics

Sadia L'Bouch

Senior Director, Manufacturing and Supply
Sangamo Therapeutics

Sadia L'Bouch

Senior Director, Manufacturing and Supply
Sangamo Therapeutics
 

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit
200+
Attendees
25+
Speakers
15+
1-to-1 Meetings Available per Attendee

Cell Therapy Event Gallery

CAR-T image gallery

TESTIMONIALS

CAR-T USA testimonials

WHO WILL BE THERE

Network with industry experts from:

  • Big pharma and biotech
  • Cell Therapy Academics and clinicians 
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers - CRO’s, Consultants, Government

Past attendees include:

CAR-T Usa Logo Cloud

The Agenda

If you’re working on autologous or allogenic cell therapies, The Vein-to-Vein Congress will cover a diverse range of cell types including NK, CAR-T, stem and placental cells.
The global cell and gene therapy market is projected to surpass $35B by 2026 and with investment in the space increasing 64% in the last two years It’s obvious there’s huge commercial potential. The question is, with the cost of cell therapies at a premium, how can the industry reduce COGS and facilitate a mass role out? There are clear bottlenecks that exist across the industry; scale-up of manufacturing, logistics, raw material supply, regulation and automation of processes are all posing real headaches to the rapidly growing field.
The Vein-to-Vein Congress EU will focus on providing actionable solutions to these bottlenecks through case studies and interactive panel sessions with leaders in cell therapy who’ve been through the same challenges that you’re experiencing. Whether you’re streamlining logistics, scaling and automating manufacturing processes or developing robust raw material supply chains, join 100+ CTOs, COOs, Heads of Manufacturing, QC and Supply Chain who’ve been there and done just that.
Take away actionable insights from a range of cell therapy types including:
· Building an in-house cell therapy manufacturing facility with Markwin Velders of Kite Pharma
· Upscaling manufacturing for clinical and commercial manufacturing with Ali Mohamed of Immatics.
· Ensuring a reliable and traceable supply of quality GMP starting and raw material with David Sourdive of Cellectis.
· Streamlining cell therapy manufacture through automation and integration of instruments with Fabio Fachin of Takeda.
· Establishing end to end accountability of materials and product from vein to vein with Volker Huppert of Glycostem.

Download Agenda

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Thursday, September 19, 2019 to Friday, January 31, 2020
Academics/Clinicians: NK Pre-Conference Day
£399 + VAT
Must be a full time academic or healthcare professional
1 Day conference pass
Networking opportunities
Refreshments, breakfast and lunch
Thursday, September 19, 2019 to Friday, January 31, 2020
Biotechs: NK Pre-Conference Day
£499 + VAT
Revenue under £5m
1 Day conference pass
Networking opportunities
Refreshments, breakfast and lunch
Thursday, September 19, 2019 to Friday, January 31, 2020
Industry/Service Provider: NK Day
£999 + VAT
Upgrade full conference ticket for £499 + VAT
1 Day conference pass
Networking opportunities
Refreshments, breakfast and lunch
Preparing registration...

Expertise Partner

Innovation Partner

Event Partner

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Other events you might be interested in:

CAR-T Congress EU 2019

Therapeutic Genome Editing Congress

European Protein Degradation Congress